Ursula Kassner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4567567/publications.pdf

Version: 2024-02-01

31	598	516215 16	610482 24
papers	citations	h-index	g-index

34	34	34	937
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors. Cardiovascular Research, 2022, 118, 2103-2111.	1.8	20
2	PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks. American Journal of Cardiovascular Drugs, 2021, 21, 83-92.	1.0	16
3	Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk. Vascular Pharmacology, 2020, 135, 106804.	1.0	10
4	Chylomicronemia From GPIHBP1 Autoantibodies Successfully Treated With Rituximab: A Case Report. Annals of Internal Medicine, 2020, 173, 764-765.	2.0	11
5	Mutation spectrum and polygenic score in German patients with familial hypercholesterolemia. Clinical Genetics, 2020, 98, 457-467.	1.0	13
6	Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study. Lipids in Health and Disease, 2020, 19, 92.	1.2	22
7	Evaluation of the role of STAP1 in Familial Hypercholesterolemia. Scientific Reports, 2019, 9, 11995.	1.6	17
8	Clinical outcome of a patient with lysosomal acid lipase deficiency and first results after initiation of treatment with Sebelipase alfa: A case report. Molecular Genetics and Metabolism Reports, 2019, 20, 100479.	0.4	2
9	Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study. Vascular Pharmacology, 2019, 116, 8-15.	1.0	20
10	Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis. Nutrients, 2019, 11, 363.	1.7	7
11	The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption. Journal of Lipid Research, 2019, 60, 161-167.	2.0	16
12	Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the First Patient Treated with Alipogene Tiparvovec Under Daily Practice Conditions. Human Gene Therapy, 2018, 29, 520-527.	1.4	27
13	Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry. Atherosclerosis, 2018, 277, 314-322.	0.4	27
14	Effect of Omega-3 Fatty Acid Supplementation on Oxylipins in a Routine Clinical Setting. International Journal of Molecular Sciences, 2018, 19, 180.	1.8	21
15	Performance characterization of a novel electronic number connection test to detect minimal hepatic encephalopathy in cirrhotic patients. European Journal of Gastroenterology and Hepatology, 2017, 29, 456-463.	0.8	12
16	CaRe high â€“ Cascade screening and registry for high cholesterol in Germany. Atherosclerosis Supplements, 2017, 30, 72-76.	1.2	12
17	Quality of life in patients treated with lipoprotein apheresis. Journal of Clinical Lipidology, 2016, 10, 323-329.e6.	0.6	18
18	Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia. Atherosclerosis, 2016, 253, 88-93.	0.4	35

#	Article	IF	Citations
19	Immunoadsorption of Agonistic Autoantibodies Against Î±1â€Adrenergic Receptors in Patients With Mild to Moderate Dementia. Therapeutic Apheresis and Dialysis, 2016, 20, 523-529.	0.4	19
20	Higher Lipoprotein (a) Levels Are Associated with Better Pulmonary Function in Community-Dwelling Older People â€“ Data from the Berlin Aging Study II. PLoS ONE, 2015, 10, e0139040.	1.1	7
21	Severe hypertriglyceridemia in a patient heterozygous for a lipoprotein lipase gene allele with two novel missense variants. European Journal of Human Genetics, 2015, 23, 1259-1261.	1.4	9
22	Lipoprotein(a) â€“ An independent causal risk factor for cardiovascular disease and current therapeutic options. Atherosclerosis Supplements, 2015, 18, 263-267.	1.2	54
23	Clinical utility gene card for: Hyperlipoproteinemia, TYPE II. European Journal of Human Genetics, 2014, 22, 953-953.	1.4	10
24	Does Regular Lipid Apheresis in Patients With Isolated Elevated Lipoprotein(a) Levels Reduce the Incidence of Cardiovascular Events?. Artificial Organs, 2014, 38, 135-141.	1.0	70
25	Dusty Punch Cards and an Eternal Enigma: High-Density Lipoproteins and Atherosclerosis. Drugs, 2014, 74, 513-520.	4.9	0
26	Therapeutic Potential of Mipomersen in the Management of Familial Hypercholesterolaemia. Drugs, 2012, 72, 1445-1455.	4.9	28
27	Single Lipoprotein Apheresis Session Improves Cardiac Microvascular Function in Patients With Elevated Lipoprotein(a): Detection by Stress/Rest Perfusion Magnetic Resonance Imaging. Therapeutic Apheresis and Dialysis, 2009, 13, 129-137.	0.4	30
28	Autosomal Recessive Hypercholesterolemia in Three Sisters with Phenotypic Homozygous Familial Hypercholesterolemia: Diagnostic and Therapeutic Procedures. Therapeutic Apheresis and Dialysis, 2004, 8, 275-280.	0.4	11
29	An ellipsometry-based Alzheimer plaque mimic: Effect of Î²-amyloid, lipoprotein identity and apolipoprotein E isoform. Journal of Colloid and Interface Science, 2004, 276, 503-506.	5.0	7
30	Molecular characterization of familial hypercholesterolemia in German and Greek patients. Human Mutation, 2004, 23, 285-286.	1.1	39
31	Two novel LDL receptor mutations in familial hypercholesterolemia: C122Y and E296X. Human Mutation, 2001, 17, 354-354.	1.1	4